JPWO2020204033A1 - - Google Patents
Info
- Publication number
- JPWO2020204033A1 JPWO2020204033A1 JP2021512150A JP2021512150A JPWO2020204033A1 JP WO2020204033 A1 JPWO2020204033 A1 JP WO2020204033A1 JP 2021512150 A JP2021512150 A JP 2021512150A JP 2021512150 A JP2021512150 A JP 2021512150A JP WO2020204033 A1 JPWO2020204033 A1 JP WO2020204033A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019070120 | 2019-04-01 | ||
| JP2019070120 | 2019-04-01 | ||
| PCT/JP2020/014832 WO2020204033A1 (ja) | 2019-04-01 | 2020-03-31 | がん治療用医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020204033A1 true JPWO2020204033A1 (https=) | 2020-10-08 |
| JPWO2020204033A5 JPWO2020204033A5 (https=) | 2023-02-20 |
| JP7549889B2 JP7549889B2 (ja) | 2024-09-12 |
Family
ID=72668636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512150A Active JP7549889B2 (ja) | 2019-04-01 | 2020-03-31 | がん治療用医薬 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220193064A1 (https=) |
| EP (1) | EP3949990A4 (https=) |
| JP (1) | JP7549889B2 (https=) |
| KR (1) | KR20210144767A (https=) |
| CN (1) | CN113660954B (https=) |
| AU (1) | AU2020255907A1 (https=) |
| CA (1) | CA3135157A1 (https=) |
| IL (1) | IL286680A (https=) |
| TW (1) | TWI862564B (https=) |
| WO (1) | WO2020204033A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4226945A4 (en) * | 2020-10-05 | 2024-10-23 | Chiome Bioscience, Inc | MEDICINES FOR THE TREATMENT OF CANCER |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014054820A1 (ja) * | 2012-10-03 | 2014-04-10 | 株式会社リブテック | in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| DE60137273D1 (de) | 2000-10-20 | 2009-02-12 | Eisai R&D Man Co Ltd | Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten |
| CN1304046C (zh) * | 2004-06-29 | 2007-03-14 | 上海人类基因组研究中心 | 肝癌相关基因dlk1及其应用 |
| CN103073641B (zh) * | 2006-11-10 | 2015-01-21 | 株式会社立富泰克 | 在体内具有抗肿瘤活性的抗人Dlk-1抗体 |
| ES2527521T3 (es) * | 2008-03-17 | 2015-01-26 | Livtech Inc. | Anticuerpos antihumanos frente a Dlk-1 que tienen actividad antitumoral |
| KR102091871B1 (ko) | 2012-07-26 | 2020-03-20 | 덴카 주식회사 | 수지 조성물 |
| SI3579883T1 (sl) * | 2017-02-08 | 2021-12-31 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protitelo |
-
2020
- 2020-03-31 AU AU2020255907A patent/AU2020255907A1/en active Pending
- 2020-03-31 TW TW109110983A patent/TWI862564B/zh active
- 2020-03-31 CN CN202080026567.XA patent/CN113660954B/zh active Active
- 2020-03-31 KR KR1020217033277A patent/KR20210144767A/ko active Pending
- 2020-03-31 WO PCT/JP2020/014832 patent/WO2020204033A1/ja not_active Ceased
- 2020-03-31 US US17/599,820 patent/US20220193064A1/en active Pending
- 2020-03-31 EP EP20784328.5A patent/EP3949990A4/en active Pending
- 2020-03-31 JP JP2021512150A patent/JP7549889B2/ja active Active
- 2020-03-31 CA CA3135157A patent/CA3135157A1/en active Pending
-
2021
- 2021-09-26 IL IL286680A patent/IL286680A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014054820A1 (ja) * | 2012-10-03 | 2014-04-10 | 株式会社リブテック | in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体 |
Non-Patent Citations (1)
| Title |
|---|
| KUDO, MASATOSHI ET AL.: "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular car", LANCET, vol. 391, JPN6020016076, 2018, pages 1163 - 73, ISSN: 0005243370 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3135157A1 (en) | 2020-10-08 |
| EP3949990A1 (en) | 2022-02-09 |
| KR20210144767A (ko) | 2021-11-30 |
| CN113660954B (zh) | 2025-01-14 |
| IL286680A (en) | 2021-10-31 |
| AU2020255907A1 (en) | 2021-10-28 |
| CN113660954A (zh) | 2021-11-16 |
| US20220193064A1 (en) | 2022-06-23 |
| JP7549889B2 (ja) | 2024-09-12 |
| WO2020204033A1 (ja) | 2020-10-08 |
| TW202104259A (zh) | 2021-02-01 |
| EP3949990A4 (en) | 2023-02-08 |
| TWI862564B (zh) | 2024-11-21 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210924 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230209 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230209 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240123 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240307 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240513 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240806 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240826 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7549889 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |